JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells

Blood

Volumn 103, Issue 9, 2004, Pages 3496-3502

  Davison, Kelly ^b   Mann, Koren K ^b   Waxman, Samuel ^b   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DICOUMAROL; DOXORUBICIN; GLUTATHIONE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FIBROBLAST; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION;

EID: 1942456821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1412     Document Type: Article

References (35)

1. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
2. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663-674.
3. Miller WH Jr, Warrell RP Jr, Frankel SR, et al. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-transretinoic acid. J Natl Cancer Inst. 1990;32:1932-1933.
4. Raelson JV, Nervi C, Rosenauer A, et al. The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 1996;88:2826-2832.
5. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990;76:1704-1709.
6. Mann KK, Shao W, Miller WH Jr. The biology of acute promyelocytic leukemia. Curr Oncol Rep. 2001;3:209-216.
7. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WHJ. Altered ligand binding and transcriptional regulation by mutations in the PML/ RAR ligand-binding domain arising in retinoic-acid-resistant patients with acute promyelocytic leukemia. Blood. 2000;96:3200-3208.
8. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant APL subclone expresses a dominant negative PML-RARα mutation. Blood. 1997;89:4282-4289.
9. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. A novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in APL. Exp Hematol. 2001;29:864-872.
10. Duprez E, Benon G, Flexor M, Lallehaug J, Lanotte M. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia. 2000;14:255-261.
11. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): I. arsenic trioxide exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345-3353.
12. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
13. Soignet SL, Maslak P, Wang Z, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Eng J Med. 1998;339:1341-1348.
14. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-713.
15. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
16. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268-277.
17. Davison K, Cote S, Mader S, Miller WH Jr. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia. 2003;17:931-940.
18. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996;15:6269-6279.
19. Namgung U, Xia Z. Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J Neurosci. 2000;20:6442-6451.
20. Huang C, Ma W, Li J, Dong Z. Arsenic induces apoptosis through a c-jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 1999;59:3053-3058.
21. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
22. Nishina H, Fischer KD, Radvanyi L, et al. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature. 1997;385:350-353.
23. Hardin JA, Sherr DH, DeMaria M, Lopez PA. A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation. J Immunol Methods. 1992;154:99-107.
24. Cross JV, Deak JC, Rich EA, et al. Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem. 1999;274:31150-31154.
25. Hochedlinger K, Wagner EF, Sabapathy K. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene. 2002;21:2441-2445.
26. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-874.
27. Qu W, Bortner CD, Sakurai T, Hobson MJ, Waalkes MP. Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway. Carcinogenesis. 2002;23:151-159.
28. Tobiume K, Matsuzawa A, Takahashi T, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001;2:222-228.
29. Porter AC, Fanger GR, Vaillancourt RR. Signal transduction pathways regulated by arsenate and arsenite. Oncogene. 1999;18:7794-7802.
30. Wada T, Nakagawa K, Watanabe T, et al. Impaired synergistic activation of stress-activated protein kinase SAPK/JNK in mouse embryonic stem cells lacking SEK1/MKK4: different contribution of SEK2/MKK7 isoforms to the synergistic activation. J Biol Chem. 2001;276:30892-30897.
31. Nobori K, Ito H, Tamamori-Adachi M, et al. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol. 2002;34:1387-1397.
32. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int J Cancer. 1999;80:417-424.
33. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 1999;19:8469-8478.
34. Lei K, Nimnual A, Zong WX, et al. The Bax sub-family of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol. 2002;22:4929-4942.
35. Muscarella DE, Bloom SE. Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol Sci. 2002;68:82-92.